- 全部删除
- 您的购物车当前为空
Atezolizumab 属于抗体抑制剂,是一种人源化单克隆抗体 IgG1,靶向 PD-L1,阻断 PD-L1 与 PD-1 的相互作用。Atezolizumab 具有抗肿瘤活性,促进 T 细胞攻击肿瘤细胞。
为众多的药物研发团队赋能,
让新药发现更简单!
Atezolizumab 属于抗体抑制剂,是一种人源化单克隆抗体 IgG1,靶向 PD-L1,阻断 PD-L1 与 PD-1 的相互作用。Atezolizumab 具有抗肿瘤活性,促进 T 细胞攻击肿瘤细胞。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 1,590 | In stock | |
5 mg | ¥ 3,980 | In stock | |
10 mg | ¥ 5,680 | In stock | |
25 mg | ¥ 8,720 | In stock | |
50 mg | ¥ 11,700 | In stock | |
100 mg | ¥ 15,800 | In stock |
Atezolizumab 相关产品
产品描述 | Atezolizumab is an antibody inhibitor, a humanized monoclonal antibody, IgG1, which targets PD-L1 and blocks the interaction of PD-L1 with PD-1. Atezolizumab has antitumor activity and promotes T-cells to attack tumor cells. |
体外活性 | 方法:MDA-MB-231、BT-20、MDA-MB-468 细胞和 T 细胞共培养,用 Atezolizumab (50-100 µg/mL) 处理 4-24 h,进行 T cell-mediated cytotoxicity assay。 |
体内活性 | 方法:为检测体内抗肿瘤活性,将 Atezolizumab (10 mg/kg) 和 Bevacizumab (5 mg/kg) 腹腔注射给携带 A2780cis 异种移植物的 BALB/C nude 小鼠,每两天一次,持续三周。 |
细胞实验 | Objective: Determine the binding of [111In]PD-L1-mAb to tumor cell lines. Cells: NCI-H2444(Lung Cancer cell line), MDAMB231(Breast Cancer cell line),etc. Concentrations: 1 μCi/100μl. Incubation Time: 1 h. Method: Incubating 1 μCi of [111In]PD-L1-mAb with 1×106cells (in triplicate for each cell line) for 1h at 37°C. PD-L1 blocking was performed by adding a 10-fold molar equivalent excess of the non-labeled mAb. After incubation, cells were washed three times with cold PBS prior to counting on an automated gamma counter. |
别名 | 阿替利珠单抗, 阿特珠单抗, 阿特朱单抗 |
分子量 | 145 kDa |
CAS No. | 1380723-44-3 |
密度 | no data available |
存储 | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Crystal structure of PD-L1 complexed with atezolizumab fab at 2.9A
案例一:将分离的CD8+T细胞与经Atezolizumab处理24小时的LoVo或HT29细胞共培养。通过乳酸脱氢酶(LDH)测定法评估CD8+T细胞对结直肠癌细胞的细胞毒性。结果发现,Atezolizumab增强了CD8T+细胞对LoVo和HT29细胞的细胞毒性。
引用文献:Chen Z, Wu Z, Wu M, et al.LncRNA SNHG16 Drives PD-L1-Mediated Immune Escape in Colorectal Cancer through Regulating miR-324-3p/ELK4 Signaling.Biochemical Genetics.2024: 1-20.
案例二:将AMM16细胞分别转染siRNA ctrl(对照组)或siRNA AR(AR敲低组)。转染后,将细胞用不同浓度Atezolizumab(0、5、10、35 μg/mL)处理。通过乳酸脱氢酶(LDH)释放实验检测细胞毒性,发现AR 敲低能增强 Atezolizumab的细胞毒作用。
引用文献:Di Donato M, Cristiani C M, Capone M, et al.Role of the androgen receptor in melanoma aggressiveness.Cell Death & Disease.2025, 16(1): 34.
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容